LOS ANGELES, March 2, 2015 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTCQB:VDRM) (The Company), a specialty pharmaceutical company devoted to bringing new products to market, is excited to start participating in test trials with a major Food and Drug Administration (FDA) approved toenail fungus treatment.
Onychomycosis is a fungal infection of the toenails or fingernails that may involve any part of the nail itself. This infection can cause pain, distress, and deformity that could produce serious physical and occupational restrictions, as well as affect quality of life.
Recently registered as a medication by the FDA, TetraStem is a liquid tetracycline-based antibiotic that is designed to treat cuts, scrapes, and burns. TetraStem has also shown success in treating diabetic foot sores, acne, and fighting methicillin-resistant Staphylococcus aureus (MRSA)infections.
ViaDerma introduced an upcoming trial, slotted to take place this coming spring, that will feature their lead product, TetraStem, against a well-known prescription treatment for Onychomycosis. Trials will begin taking place with patients receiving both treatments at 90-day, six months, nine months, and one year lapses of time. Previously used as an off-label treatment for Onychomycosis with proven results, ViaDerma believes that TetraStem will serve as a possible more effective and more affordable option than other leading brands.
TetraStem has been seen in private off-label practice to hold an 86% success rate after only 12 weeks of use. In comparison, the competition has only seen an 18% success rate, requiring 48 weeks of patient use. Not only are these differences staggering, but to add to that, a bottle of TetraStem retails for only $39.99, whereas the same size has been sold for more than $500 through other brands.
"We are excited about expanding our lead product to treat an ever-expanding list of needs of patients who may be looking for new treatment options," commented Dr. Christopher Otiko, CEO of ViaDerma. "I believe, with high hopes, that these trials will produce the results that we, as a company, have been awaiting."
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com .
Forward Looking Statements
This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements regarding the outlook of the Company's business and results of operations. By nature, these risks and uncertainties could cause actual results to differ materially from those indicated. Generally speaking, any statements using terms such as "will," "expect," "anticipate," or "may," or which otherwise predict or address future results or events, are likely to contain forward-looking statements. It is important to note that actual results may differ materially from what is indicated in any forward-looking statement. Readers should consider any forward-looking statements in light of factors that could cause actual results to vary. These factors are described in our filings with the SEC, and readers should refer to those filings, including Risk Factors described in those filings, in connection with any forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Dr. Christopher Otiko Chief Executive Officer ViaDerma, Inc. 818-836-2475
